fda warns against semaglutide The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications FDA warns consumers not to

Research into the efficacy of GLP-1 drugs found that, in a clinical trial setting, Semaglutide (Ozempic and Wegovy) could result in a 14.9% reduction in body weight over the course of 68 weeks

Best for researchers who want the most granular dose control

Primary Care (DPC) Direct primary care with longer appointments, direct physician access, and no insurance red tape

NAION typically causes sudden, painless vision loss in one eye and may also produce blind spots, reduced peripheral vision, diminished color perception, or permanent visual impairment

Hydration is key for weight loss and overall health

Supplies Important notes Always use a new, sterile syringe for each injection and dispose of it in a sharps container